Cadrenal Therapeutics Q3 2026 Earnings Date & Estimates

Cadrenal Therapeutics (NASDAQ:CVKD) is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cardiovascular disease. The company’s lead product candidate is tecarfarin, an investigational oral anticoagulant intended for people who require long-term blood-thinning treatment, including patients with implanted mechanical heart valves and left ventricular assist devices.

Tecarfarin is designed as a vitamin K antagonist and is metabolized primarily through carboxylesterase 1 rather than the cytochrome P450 pathway associated with many drug interactions involving warfarin. Cadrenal is evaluating whether this mechanism may offer a treatment alternative for patients who face challenges with existing anticoagulant therapies. Tecarfarin has not been approved for commercial use, and its safety and effectiveness remain subject to clinical development and regulatory review.

Cadrenal Therapeutics was established to advance tecarfarin and related cardiovascular applications. The company is headquartered in Ponte Vedra Beach, Florida, and is led by Quang Pham, who serves as chairman and chief executive officer. Its activities are centered on research, clinical development, regulatory engagement and potential commercialization of therapies for specialized cardiovascular patient populations.